What is DCTH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DCTH?

P/E (TTM) is 997.59 and 52-week range is $8.12 to $17.42 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DCTH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DCTH?

The company profile lists revenue (TTM) near $83M, net income (TTM) near $46M, EPS (TTM) near $0.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Delcath Systems Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Queensbury, New York, US, 34.5M shares outstanding, ISIN US24661P8077 when available from company profile and filing metadata.

Delcath Systems Inc

$DCTH

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$15.36

+2.13%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 156 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Employees

156

Website

delcath.com/

IPO

2000-10-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)